Joyce O’Shaughnessy, MD

Articles

Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

February 13th 2023

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

February 13th 2023

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

February 7th 2023

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

February 7th 2023

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

January 30th 2023

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

January 30th 2023

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

Neoadjuvant Treatment of HER2+ Early Breast Cancer

January 20th 2023

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

January 20th 2023

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.